NovaXS Biotech Corp.

Led by a professional team in healthcare with a proven track record of over 40 million fundraising experience and 5 successful busines exits, NovaXS Biotech is on a mission to optimize patients’ medication self-administration experience and improve treatment outcomes. Our patent-pending technology, Telosis, is a patient-centric closed-loop drug delivery bio pharma solution that helps patients deliver medications subcutaneously or intramuscularly without a needle and manage their chronic condition and medication adherence on the patient engagement APP. The technology could also help pharmaceutical partners reduce their COG by 30%, increase revenue with improved patient compliance, and boost efficacy of medication with better absorption rate. Current partners and investors include Baxter, Edward-Elmhurst Health, Helixmith, etc.

Website

https://www.novaxs.co/

External link for NovaXS Biotech Corp.

Industry

Biotechnology Research

Company size

2-10 employees

Headquarters

Berkeley, CA

Type

Privately Held

Founded

2021

Specialties

biotech, medical device, healthcare, needle-free, drug delivery, gene therapy, and Duchenne muscular dystrophy